Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;63(6):868-873.
doi: 10.1002/mus.27220. Epub 2021 Mar 16.

Thymoma pathology and myasthenia gravis outcomes

Deepak Menon  1 , Hans Katzberg  1 , Carolina Barnett  1 , Prodipto Pal  2 , Andrea Bezjak  3 , Shaf Keshavjee  4 , Vera Bril  1
Affiliations

Thymoma pathology and myasthenia gravis outcomes

Deepak Menon et al. Muscle Nerve. 2021 Jun.

Abstract

Introduction: There is limited evidence regarding the impact of World Health Organization (WHO) subtype of thymoma on post-thymectomy outcome of thymoma-associated myasthenia gravis (TAMG). The objective was to determine if the pathological subtypes of thymoma were associated with post-thymectomy outcomes of myasthenia gravis (MG), in patients with TAMG.

Methods: We performed a retrospective study of consecutive patients with TAMG who attended the neuromuscular clinic between January 2018 and December 2019 with a minimum follow-up of 1 y after thymectomy. Outcome measures were MG Impairment Index (MGII), single-simple question (SSQ), Myasthenia Gravis Foundation of America post-intervention status (MGFA PIS) and non-responder MG status at last assessment.

Results: Ninety-five patients were included; mean age at onset was 48.1 ± 12.1 y; 54(56.8%) were females. Thirteen patients developed MG post-thymectomy. The most common thymoma was WHO type B2 in 39 (41.1%). Most patients (40, 42.1%) had Masaoka stage II thymoma. There was no association of thymoma subtypes or Masaoka stage of disease with age, gender, MG phenotype, serology, post-thymectomy onset, interval from onset to thymectomy, MGII, SSQ, MGFA PIS, or non-responder status. Associations were found between positive serology and lower MGII (11.1 ± 14.2 vs 23 ± 12.9, P = .050), thymic follicular hyperplasia (TFH) and higher SSQ (89.3 ± 11.7 vs 80.1 ± 20.2, P-.043), and lack of recurrence and higher SSQ (84.1 ± 18 vs 72.5 ± 20, P = .037).

Discussion: The WHO pathological subtype of thymoma did not correlate with MG outcomes. However, positive acetylcholine antibody serology, presence of TFH, and non-recurrence of thymoma predict a favorable outcome.

Keywords: myasthenia gravis; outcomes; staging; thymectomy; thymoma subtype.

PubMed Disclaimer

References

REFERENCES

    1. Weksler B, Lu B. Alterations of the immune system in Thymic malignancies. J Thorac Oncol [online serial]. 2014;9:S137-S142. http://www.sciencedirect.com/science/article/pii/S1556086415333372. Accessed June 13, 2020.
    1. Marx A, Ströbel P, Weis C-A. The pathology of the thymus in myasthenia gravis. Mediastinum [online serial]. 2018;2. http://med.amegroups.com/article/view/4646. Accessed June 7, 2020.
    1. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology [online serial]. 2016;87:419-425. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114/. Accessed May 30, 2020.
    1. Marx A, Chan JKC, Coindre J-M, et al. WHO classification of tumors of the thymus: continuity and changes. J Thorac Oncol [online serial]. 2015;10:1383-1395. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581965/. Accessed June 7, 2020.
    1. den Bakker MA, Roden AC, Marx A, Marino M. Histologic classification of Thymoma: a practical guide for routine cases. J Thorac Oncol [online serial]. 2014;9:S125-S130. https://www.jto.org/article/S1556-0864(15)33335-9/abstract. Accessed June 8, 2020.

LinkOut - more resources